Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/5/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) Delayed: 66.53 +0.10 (0.15%)
Previous Close $66.43    52 Week High $108.96 
Open $65.79    52 Week Low $62.12 
Day High $66.64    P/E N/A 
Day Low $65.52    EPS $-1.27 
Volume 2,299,209       

Medivation, Inc. (NASDAQ: MDVN) Delayed: 81.44 --0 (-0%)
Previous Close $81.44    52 Week High $81.48 
Open $3852.47    52 Week Low $26.41 
Day High $81.44    P/E N/A 
Day Low $81.44    EPS $-1.03 
Volume 13,593       

BANCO SANTANDER S.A. (NYSE: SAN) Delayed: 14.93 -0.12 (0.8%)
Previous Close $15.05    52 Week High $5.58 
Open $14.90    52 Week Low $3.60 
Day High $14.97    P/E N/A 
Day Low $14.86    EPS $0.00 
Volume 8,277,569       

SANOFI (NASDAQ: SNY) Delayed: 44.24 -0.09 (0.2%)
Previous Close $44.33    52 Week High $44.76 
Open $44.17    52 Week Low $36.81 
Day High $44.36    P/E N/A 
Day Low $44.03    EPS $0.00 
Volume 1,695,037